All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
AACR 2017: Poster 515/1 – PI3P and cAMP pathway alterations in AML patients
A poster session titled “Oncogenic Growth Factors and Signal Transducers” took place at the 107th American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA on Sunday 3rd April.
Uncontrolled activation of genes involved in the Phosphatidylinositol 3-Phosphate (PI3P) pathway via PI3K/AKT/mTOR are associated with oncogenic activity and poor survival.1 Additionally, dysregulation of AMP-Activated Protein Kinase (AMPK), a regulator of cell homeostasis, has been reported to play a role in Acute Myeloid Leukemia (AML).2
Mariachiara Abbenante from the University of Bologna, Bologna, Italy, and colleagues investigated the effect of PI3P and AMPK pathways in AML. In total, 208 newly diagnosed AML patients were screened for TP53, FLT3, NPMI, IDH1, IDH2, and DNMTA mutations.
The key results were:
- Alterations in the P13K/AKT/mTOR pathway and AMPK pathway reported in 48% of patients (103/209)
- Overall Survival (OS) was significantly worse in patients with alterations in the P13K/AKT/mTOR pathway compared to unaltered patients; P = 0.035
- OS was significantly worse in patients with alterations in the AMPK pathway compared to unaltered patients; P < 0.001
- Lower percentage of Complete Remission (CR) was associated with alterations of regulators in cyclic AMP (cAMP [increases the activity of AMPK]) pathway; P < 0.001
- TP53 mutations, age, secondary AML, and karyotype were significantly associated with alterations of regulators in cAMP; P = 0.009
In summation, alterations in the PI3P and cAMP pathways are associated with poor prognosis in AML patients. Moreover, alterations in the cAMP pathway is associated with therapy resistance in AML.
References